Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy Compounding topic
No spam. Unsubscribe anytime.
Pharmacy compounding rule draws strong opposition; committee pauses debate for stakeholder talks
Summary
The Board of Pharmacy's proposal to preserve interim compounding inspection checklists and reference United States Pharmacopeia (USP) standards in disciplinary considerations prompted lengthy testimony from pharmacists and associations; the subcommittee adjourned debate and asked the board and stakeholders to negotiate changes within 60–75 days.
The Board of Pharmacy asked the subcommittee to preserve the status quo inspection checklist for compounding while it completes permanent compounding rules required by 2024 legislation. A focal and contested line in the draft would allow the board to consider substantial deviations from United States Pharmacopeia (USP) chapters (nonsterile and sterile compounding, hazardous drugs, radiopharmaceuticals) when those deviations "impacted public safety," potentially as evidence in disciplinary proceedings.
Pharmacy stakeholders including Brian Clark (South Carolina Pharmacy Association), Addison Livingston (independent pharmacies) and others warned that such language, as written, could effectively adopt USP chapters as enforceable law without a transition period, impose costly upgrades, reduce access to compounded medicines in rural and independent pharmacies, and leave vague standards such as "serious deviation" or "substantial deviation" subject to inconsistent enforcement. "This would impose costly and complex standards without adequate clarity or transition," Brian Clark said.
Board representatives (including Dr. Shuler Spagna and Casey Shealy, board executive) said the intent was to maintain the status quo while allowing the board to consider expert review under a standard‑of‑care model when investigations indicate patient safety risk. They emphasized the proposal was meant as a temporary placeholder until final rules are promulgated and said they would convene the compounding advisory panel.
After extensive testimony and questioning, the subcommittee voted to adjourn debate and directed the Board of Pharmacy, LLR and pharmacy stakeholders to meet and attempt to reach compromise language within an agreed window (committee discussed 60–75 days) to avoid automatic promulgation. The committee emphasized it did not intend to force a compromised language that would harm patient access or safety and required written points of concern from stakeholders.
